» Articles » PMID: 25380886

FGF23 and Klotho in Relation to Markers of Endothelial Dysfunction in Kidney Transplant Recipients

Overview
Journal Transplant Proc
Specialty General Surgery
Date 2014 Nov 9
PMID 25380886
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Fibroblast growth factor (FGF) 23 is a newly discovered member of the FGF family. Klotho is a cofactor of FGF23. Activation of the FGF23-Klotho system is responsible for negative phosphate balance. In addition, FGF23 appears to be a risk factor for cardiovascular complications. The aim of this study was to assess levels of FGF23 and Klotho in stable kidney transplant recipients on triple immunosuppressive therapy in relation to comorbidities and markers endothelial dysfunction. Healthy volunteers served as a control group.

Methods: Hemoglobin, urea, and creatinine were studied with the use of standard laboratory methods in the hospital central laboratory. We assessed FGF23 and Klotho, markers of endothelial function/injury von Willebrand factor (vWF), intercellular adhesion molecule (ICAM), vascular cell adhesion molecule (VCAM), and interleukin (IL) 6, N-terminal pro-B-type natriuretic peptide (NT-proBNP) and copeptin with the use of commercially available assays.

Results: FGF23 was significantly higher and Klotho significantly lower in kidney transplant recipients compared with healthy volunteers. FGF23 correlated with copeptin (r = 0.28; P < .05), IL-6 (r = 0.39; P < .01), VCAM (r = 0.36; P < .01), time after transplantation (r = 0.31; P < .05), platelet count (r = 0.31; P < .05), mean corpuscular volume (r = -0.40; P < .01), and phosphate (r = 0.31; P < .05). Klotho correlated with NT-proBNP (r = 0.38; P < .01), vWF (r = -0.26; P < .05), calcium (r = -0.39; P < .01), and age (r = 0.45; P < .001). FGF23 was significantly higher and Klotho significantly lower in patients with estimated glomerular filtration rate (eGFR) >60 mL/min compared with patients with eGFR <60 mL/min.

Conclusions: Disturbances in the FGF23-Klotho system appeared to be related to the endothelial cell injury. Thus they are involved not only in pathogenesis of the metabolic bone disease but also in cardiovascular complications, particularly in kidney disease.

Citing Articles

Fibroblast Growth Factors in Cardiovascular Disease.

Morita H, Hoshiga M J Atheroscler Thromb. 2024; 31(11):1496-1511.

PMID: 39168622 PMC: 11537794. DOI: 10.5551/jat.RV22025.


Klotho and Fibroblast Growth Factor 23 Are Independent of Vitamin D, and Unlike Vitamin D, Are Not Associated With Graft- and Patient Survival After Kidney Transplantation.

Thorsen I, Bleskestad I, Asberg A, Jonsson G, Skadberg O, Heldal K Transplant Direct. 2023; 9(9):e1522.

PMID: 37575950 PMC: 10414697. DOI: 10.1097/TXD.0000000000001522.


Cholecalciferol supplementation effectively improved tertiary hyperparathyroidism, FGF23 resistance and lowered coronary calcification score: a prospective study.

Hu S, Bai Y, Li Y, Tao Y, Wang X, Lin T Endocr Connect. 2022; 11(8).

PMID: 35904219 PMC: 9346334. DOI: 10.1530/EC-22-0123.


The Role of Alterations in Alpha-Klotho and FGF-23 in Kidney Transplantation and Kidney Donation.

Gupta M, Orozco G, Rao M, Gedaly R, Malluche H, Neyra J Front Med (Lausanne). 2022; 9:803016.

PMID: 35602513 PMC: 9121872. DOI: 10.3389/fmed.2022.803016.


Uremic Toxins, Oxidative Stress, Atherosclerosis in Chronic Kidney Disease, and Kidney Transplantation.

Wojtaszek E, Oldakowska-Jedynak U, Kwiatkowska M, Glogowski T, Malyszko J Oxid Med Cell Longev. 2021; 2021:6651367.

PMID: 33628373 PMC: 7895596. DOI: 10.1155/2021/6651367.